TMDX earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E 14.16. Updated 2026-07-23.
TransMedics Group (TMDX) Research Hub
TransMedics Group (TMDX) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 82.18 USD (-4.88%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 14.16, market cap 2.46B. This hub links to the full technical, earnings and options research available for TMDX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 82.18 USD (-4.88%) |
| 52-week range | 64.84 USD – 95.18 USD |
| Trend regime | Range |
| 14-day RSI | 47.9 (Neutral) |
| Trailing P/E | 14.16 |
| Market cap | 2.46B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for TMDX
Covered Call on TMDX: how it works, illustrative setup around the real 82.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TMDX: how it works, illustrative setup around the real 82.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TMDX: how it works, illustrative setup around the real 82.18 USD price, max profit/loss, breakeven and when to use it. Educational.
TMDX technical analysis: range, last 82.18 USD, RSI 47.9, 52w range 64.84 USD–95.18 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TMDX in?
TransMedics Group (TMDX) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is TMDX in an uptrend or downtrend?
As of 2026-09-11, TMDX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TMDX's trailing P/E ratio?
TMDX's trailing P/E is 14.16, with a market cap of 2.46B. See the earnings research page for full valuation detail.
When does TMDX next report earnings?
TMDX is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of 0.5 USD.